Sign in Subscribe
European Union

European Investment Bank Signs €150 Million Loan Agreement with Alfasigma to Support R&D Investments

Strategic Insights

— 1 min read

The European Investment Bank (EIB) has signed a €150 million loan agreement with Alfasigma, a global pharmaceutical company founded in Italy, to support the company's research and development (R&D) investments over the next three years. The funds will help Alfasigma develop and market new medicines in its main therapeutic areas, including rare diseases and specialty care.

Key Takeaways:

  • The EIB financing will support Alfasigma's R&D activities for the three-year period from 2025 to 2027, focusing on new treatments in gastroenterology and hepatology, vascular medicine, and rheumatology.
  • The operation aims to accelerate the translation of scientific advances into patient-centered solutions, addressing unmet needs and delivering high-impact health outcomes.
  • The EIB financing is part of the bank's strategy to bolster competitiveness and innovation in the European healthcare sector and create highly skilled jobs.
  • The loan agreement was announced by EIB Vice-President Gelsomina Vigliotti and Alfasigma's Chief Financial Officer Tatiana Simonelli.
  • Alfasigma operates in over 100 markets worldwide and has offices and production sites in several countries, including Italy, Spain, and the United States.
  • The company employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products.

Statistics:

  • The EIB loan agreement totals €150 million.
  • The financing will support Alfasigma's R&D activities for the three-year period from 2025 to 2027.
  • The EIB Group signed over 900 projects worth nearly €89 billion in 2024, boosting Europe's competitiveness and security.
  • The EIB Group signed 99 operations totaling €10.98 billion in Italy in 2024, helping to unlock almost €37 billion of investment in the real economy.
  • Almost 60% of the EIB Group's annual financing supports projects directly contributing to climate change mitigation, adaptation, and a healthier environment.

Sources:

  • European Investment Bank
  • European Investment Bank Group
  • Alfasigma

Read more